Pharma News

Two years into the pandemic, health systems are still facing significant challenges in providing essential health services. Ongoing disruptions have been reported in over 90 percent of countries surveyed in the third round of WHOs Global pulse survey on continuity of essential health services during the COVID-19 pandemic.

The U.S. Food and Drug Administration FDA has approved Enjaymo sutimlimab-jome to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease CAD. Enjaymo is the first and only approved treatment for people with CAD and works by inhibiting the destruction of red blood cells hemolysis.

Medidata, a Dassault Systèmes company, announced today that Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership. This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralized clinical trial technology (DCT) for the life sciences industry.

Dr. Reddy's Laboratories Ltd announced that it has entered into a definitive agreement to acquire Nimbus Health GmbH. Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany. Dr. Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years.

The U.S. Food and Drug Administration has approved the first generic of Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vials (eye drops) to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye). Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA).  Nuvaxovid becomes the fifth COVID-19 vaccine authorised by the UK’s independent medicines regulator.

Central Drug Research Institute (CDRI) provides exclusive licensing to Aveta Biomics, USA of its patented technology of Caviunin-based drug compositions for further clinical development and commercialization.

Worldwide, one in three women and one in five men over the age of 50 years will suffer an osteoporotic fracture. In the US alone, an estimated 10 million people over the age of 50 years have osteoporosis and one in two women in the United States will sustain a fragility fracture in her lifetime.

Vasopressin and glucocorticoids compared to placebo, improved return of spontaneous circulation among adults for in-hospital cardiac arrest, says recent findings in Resuscitation.

The Health Ministry says that Acitretin will be included in Schedule H after making an amendment in the Drugs Rules, 1945. Acitretin is an oral retinoid used in the treatment of severe resistant psoriasis.

Schedule H is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor. The manufacture and sales of all drugs are covered under the Drugs and Cosmetics Act and Rules.